echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Last week, a large number of pharmaceutical companies were reduced by shareholders

    Last week, a large number of pharmaceutical companies were reduced by shareholders

    • Last Update: 2022-12-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    This year's wave of reduction is sweeping the pharmaceutical circle, and a large number of listed pharmaceutical companies are announcing the reduction of shareholders or executives one after another, including WuXi AppTec, Inco Medical, Aotai Biologics, Huasen Pharmaceutical, Aviron and so on
    .
    Last week, a large number of pharmaceutical companies announced that they had reduced their holdings, including Zhaoyan New Drug and Heavy Drug Holdings
    .

     
    On December 16, Zhaoyan New Drug announced that Zhou Zhiwen, one of the actual controllers of the company, intends to reduce his holdings of no more than 11 million A shares, no more than 2.
    05%
    of the company's current total share capital.
    Director Zuo Conglin intends to reduce his holdings of no more than 590,000 A shares, which shall not exceed 0.
    11%
    of the company's current total share capital.

     
    It is worth noting that Zhaoyan New Drug has been reduced by many high-level executives in the past six months
    .
    Last week, it disclosed that director Gu Xiaolei has reduced his holding of 2.
    7 million A shares in the company in a block transaction, and the reduction plan has not yet been
    implemented.
    On September 22 this year, Gu Xiaolei decided to reduce his holdings within 3 months by no more than 0.
    61%
    of the company's total share capital at that time.
    According to the announcement, in the past six months, the company's directors, supervisors and core technical personnel have reduced their holdings of about 16.
    94 million A-shares, accounting for about 5.
    3%
    of the company's A-share capital based on the data reported by the report.

     
    On December 15, Heavy Medicine Holdings issued an announcement that after the market closed on the 15th, the company received Shenzhen Maoye's "Notification Letter on the Progress of the Shareholding Reduction Plan", and learned that the number of shares reduced by Shenzhen Maoye's shareholding reduction plan has exceeded half, in accordance with the "Several Provisions on the Reduction of Shareholdings by Shareholders, Directors and Supervisors of Listed Companies", "Implementation Rules for Shareholders, Directors, Supervisors and Senior Management of Listed Companies on the Shenzhen Stock Exchange" and other relevant regulations
    .
    The reduction of shares by Shenzhen Maoye stemmed from its participation in the company's major asset sale and issuance of shares in 2017, the purchase of assets and related party transactions, and the acquisition of about 173 million shares of the
    company's non-public shares.
    More than half
    of the reduction of holdings in this reduction plan has been completed.

     
    On December 13, Miratech Pharmaceutical announced that the change in equity was caused by Zhang Pei, Zhang Xiqian and Zhang Zhijun, the concerted actors of the Company's controlling shareholder, Guizhou Magic Investment Co.
    , Ltd.
    ("Magic Investment"), to reduce their holdings of 6,397,719 shares of the Company through block transactions, accounting for 1.
    20% of the Company's total share capital, without touching the tender offer
    .
    On the same day, Xianju Pharmaceutical was reduced by Shenzhen Stock Connect by 431,600 shares, and the latest holding amount was 13,831,800 shares, accounting for 1.
    40%
    of the total share capital of the company's A shares.

     
    In the eyes of the industry, the reduction of pharmaceutical companies is not new
    .
    Some shareholders of pharmaceutical companies have reduced their holdings more than 100 times in recent years, such as WuXi AppTec,
    a leading CRO company.
    According to statistics, from July 2, 2019 to September 30, 2021, WuXi AppTec shareholders have increased or decreased their holdings a total of 106 times, of which the cumulative amount of holdings has reached 32.
    61 billion yuan
    .

     
    Since the beginning of this year, WuXi AppTec has also been reduced many times, for example, in June, the company announced that the shareholders controlled by the actual controller of the company and the shareholders who signed a concerted action agreement with the actual controller will reduce their total holdings of A shares of no more than 3% of the company's total share capital, that is, no more than 88.
    6809 million shares
    .
    It will be implemented from July 4 to September 30
    .

     
    On November 25, WuXi AppTec also announced that due to its own capital needs, the shareholders controlled by the actual controller of the company and the shareholders who signed a concerted action agreement with the actual controller plan to reduce their holdings of the company's A shares through centralized bidding and/or block trading according to market conditions, and the total number of shares to be reduced will not exceed 65 million shares, that is, the total number of shares will not exceed 2.
    2%
    of the company's total share capital as of November 24, 2022.

     
    Although it has been frequently reduced, the industry generally believes that CXO head companies have a high-growth logic, and WuXi AppTec still has great development prospects
    .
    It is reported that star fund manager Gülen has continued to be optimistic about WuXi AppTec in the near future, and the China Europe Healthcare Fund managed by it has increased its position in the company
    for nearly two consecutive quarters.

     
    Industry analysts believe that the frequent reduction of holdings of pharmaceutical listed companies does not mean that the industry has passed, because there are many reasons for shareholders to reduce their holdings, including supplementary liquidity, personal financial situation, business needs, investment in new fields, and providing borrowing support for listed companies
    .
    For investors, it is necessary to carefully analyze the reasons for their reduction and the actual use of the funds to reduce their holdings, and then decide on the subsequent operation
    .

     
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.